{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-032650","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2026-08-13T12:35:22+00:00","discovered_at":"2026-08-13T12:40:00.244690+00:00","generated_at":"2026-08-13T12:40:08.417030+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PDS Biotech refocuses on PDS0301, discontinues PDS0101 Phase 3 trial; Q2 net loss $9.8M","bullets":["Q2 2026 net loss $9.8M ($0.18/share) vs $9.4M ($0.21) year-ago; cash $5.6M at June 30.","Strategic refocus: PDS0301 (IL-12 immunocytokine) becomes lead program; PDS0101 VERSATILE-003 Phase 3 trial discontinued.","Positive mCRC data: ORR 77.8% (7/9) with PDS0301 vs 35% (7/20) without; 24-month survival ~80% vs ~35%.","Company to pursue partnerships for PDS0101 development; R&D expenses down to $3.3M from $4.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-032650","json":"https://secwatch.observer/filing/0001140361-26-032650.json","markdown":"https://secwatch.observer/filing/0001140361-26-032650.md","text":"https://secwatch.observer/filing/0001140361-26-032650.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126032650/0001140361-26-032650-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126032650/ef20080122_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T12:40:08.417030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}